Roger Barker

Summary

Affiliation: University of Cambridge
Country: UK

Publications

  1. ncbi request reprint Task-set switching deficits in early-stage Huntington's disease: implications for basal ganglia function
    Adam R Aron
    University of Cambridge, UK
    J Cogn Neurosci 15:629-42. 2003
  2. pmc The Current Status of Neural Grafting in the Treatment of Huntington's Disease. A Review
    Ruwani Wijeyekoon
    Cambridge Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge Cambridge, UK
    Front Integr Neurosci 5:78. 2011
  3. pmc Parkinson's Disease in a Dish: What Patient Specific-Reprogrammed Somatic Cells Can Tell Us about Parkinson's Disease, If Anything?
    J Drouin-Ouellet
    Neuroscience Axis, CHUL Research Center CHUQ, T2 50, 2705 Boul Laurier, Quebec City, QC, Canada G1V 4G2
    Stem Cells Int 2012:926147. 2012
  4. pmc Current understanding of the glial response to disorders of the aging CNS
    Roger A Barker
    Department of Clinical Neuroscience, Cambridge Centre for Brain Repair, University of Cambridge Cambridge, UK
    Front Pharmacol 3:95. 2012
  5. ncbi request reprint Scientific and ethical issues related to stem cell research and interventions in neurodegenerative disorders of the brain
    Roger A Barker
    John van Geest Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Forvie Site Robinson Way, Cambridge CB2 0PY, United Kingdom Electronic address
    Prog Neurobiol 110:63-73. 2013
  6. pmc The long-term safety and efficacy of bilateral transplantation of human fetal striatal tissue in patients with mild to moderate Huntington's disease
    Roger A Barker
    Cambridge Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK
    J Neurol Neurosurg Psychiatry 84:657-65. 2013
  7. doi request reprint Stem cells and neurodegenerative diseases: where is it all going?
    Roger A Barker
    Cambridge Centre for Brain Repair, Department of Clinical Neuroscience, University of Cambridge, Forvie Site, Robinson Way, Cambridge CB2 OPY, UK
    Regen Med 7:26-31. 2012
  8. ncbi request reprint Fetal dopaminergic transplantation trials and the future of neural grafting in Parkinson's disease
    Roger A Barker
    Cambridge Centre for Brain Repair, Cambridge, UK
    Lancet Neurol 12:84-91. 2013
  9. pmc Visualising disease progression on multiple variables with vector plots and path plots
    Stanley E Lazic
    Cambridge Computational Biology Institute, Department of Applied Mathematics and Theoretical Physics, University of Cambridge, UK
    BMC Med Res Methodol 9:32. 2009
  10. doi request reprint Cell therapies and Parkinson's disease: where next? Interviewed by Emily Culme-Seymour
    Roger Barker
    Addenbrooke s Hospital, University of Cambridge, UK
    Regen Med 5:857-61. 2010

Collaborators

Detail Information

Publications71

  1. ncbi request reprint Task-set switching deficits in early-stage Huntington's disease: implications for basal ganglia function
    Adam R Aron
    University of Cambridge, UK
    J Cogn Neurosci 15:629-42. 2003
    ....
  2. pmc The Current Status of Neural Grafting in the Treatment of Huntington's Disease. A Review
    Ruwani Wijeyekoon
    Cambridge Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge Cambridge, UK
    Front Integr Neurosci 5:78. 2011
    ..In this review we discuss the rationale for treating HD using this approach, before discussing the clinical trial data and what we have learnt to date using this therapeutic strategy...
  3. pmc Parkinson's Disease in a Dish: What Patient Specific-Reprogrammed Somatic Cells Can Tell Us about Parkinson's Disease, If Anything?
    J Drouin-Ouellet
    Neuroscience Axis, CHUL Research Center CHUQ, T2 50, 2705 Boul Laurier, Quebec City, QC, Canada G1V 4G2
    Stem Cells Int 2012:926147. 2012
    ..In this paper, we discuss the advances made in the field of cellular reprogramming to model PD and discuss the pros and cons associated with the use of such cells...
  4. pmc Current understanding of the glial response to disorders of the aging CNS
    Roger A Barker
    Department of Clinical Neuroscience, Cambridge Centre for Brain Repair, University of Cambridge Cambridge, UK
    Front Pharmacol 3:95. 2012
    ....
  5. ncbi request reprint Scientific and ethical issues related to stem cell research and interventions in neurodegenerative disorders of the brain
    Roger A Barker
    John van Geest Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Forvie Site Robinson Way, Cambridge CB2 0PY, United Kingdom Electronic address
    Prog Neurobiol 110:63-73. 2013
    ..This includes issues to do with the source of the cells, their ownership and exploitation along with questions about patient recruitment, consent and trial design when they translate to the clinic for therapeutic use. ..
  6. pmc The long-term safety and efficacy of bilateral transplantation of human fetal striatal tissue in patients with mild to moderate Huntington's disease
    Roger A Barker
    Cambridge Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK
    J Neurol Neurosurg Psychiatry 84:657-65. 2013
    ..While no sustained functional benefit was seen, we conclude that this may relate to the small amount of tissue that was grafted in this safety study compared with other reports of more successful transplants in patients with HD...
  7. doi request reprint Stem cells and neurodegenerative diseases: where is it all going?
    Roger A Barker
    Cambridge Centre for Brain Repair, Department of Clinical Neuroscience, University of Cambridge, Forvie Site, Robinson Way, Cambridge CB2 OPY, UK
    Regen Med 7:26-31. 2012
    ..In this review, we will discuss how these developments have come about, particularly in the context of Parkinson's disease, and what this means for the future of this whole field over the next few years...
  8. ncbi request reprint Fetal dopaminergic transplantation trials and the future of neural grafting in Parkinson's disease
    Roger A Barker
    Cambridge Centre for Brain Repair, Cambridge, UK
    Lancet Neurol 12:84-91. 2013
    ..Our understanding on how best to implement this cell-replacement strategy for patients has grown, but gaining this insight has entailed critical reappraisal of data from transplant trials that have already been undertaken...
  9. pmc Visualising disease progression on multiple variables with vector plots and path plots
    Stanley E Lazic
    Cambridge Computational Biology Institute, Department of Applied Mathematics and Theoretical Physics, University of Cambridge, UK
    BMC Med Res Methodol 9:32. 2009
    ....
  10. doi request reprint Cell therapies and Parkinson's disease: where next? Interviewed by Emily Culme-Seymour
    Roger Barker
    Addenbrooke s Hospital, University of Cambridge, UK
    Regen Med 5:857-61. 2010
    ..He is a member of the CURE PD Research Advisory Panel and the MRC Stem Cell Liaison Committee. He is a member of the Regenerative Medicine editorial board and co-editor-in-chief of the journals ACNR and the Journal of Neurology...
  11. doi request reprint Graft-induced dyskinesias in Parkinson's disease: what is it all about?
    Roger A Barker
    Brain Repair Centre and Department of Neurology, University of Cambridge, Cambridge CB2 0PY, UK
    Cell Stem Cell 7:148-9. 2010
    ..Recently in Science Translational Medicine, Politis et al. (2010) demonstrate that GIDs may originate from serotoninergic neurons that are cografted in these transplants...
  12. doi request reprint Parkinson's disease and growth factors - are they the answer?
    Roger A Barker
    Cambridge Centre for Brain Repair, Forvie Site, Robinson Way, Cambridge CB2 0PY, UK
    Parkinsonism Relat Disord 15:S181-4. 2009
    ..The challenge therefore is not whether this approach works, because it self-evidently does in some patients, but rather how we can do this more consistently...
  13. ncbi request reprint The potential for circuit reconstruction by expanded neural precursor cells explored through porcine xenografts in a rat model of Parkinson's disease
    Richard J E Armstrong
    Cambridge Centre for Brain Repair, University of Cambridge, Forvie Site, Robinson Way, Cambridge, CB2 2PY, United Kingdom
    Exp Neurol 175:98-111. 2002
    ....
  14. ncbi request reprint Neurogenesis in the R6/1 transgenic mouse model of Huntington's disease: effects of environmental enrichment
    Stanley E Lazic
    Centre for Brain Repair, University of Cambridge, Cambridge CB2 2PY, UK
    Eur J Neurosci 23:1829-38. 2006
    ....
  15. ncbi request reprint Olfactory abnormalities in Huntington's disease: decreased plasticity in the primary olfactory cortex of R6/1 transgenic mice and reduced olfactory discrimination in patients
    Stanley E Lazic
    Centre for Brain Repair, University of Cambridge, CB2 2PY, UK
    Brain Res 1151:219-26. 2007
    ..These results suggest that olfactory impairments observed in HD patients may be the result of reduced plasticity in the primary olfactory cortex...
  16. ncbi request reprint Transplantation of expanded neural precursor cells from the developing pig ventral mesencephalon in a rat model of Parkinson's disease
    Richard J E Armstrong
    Cambridge Centre for Brain Repair, University of Cambridge, Forvie Site, Robinson Way, CB2 2PY, Cambridge, UK
    Exp Brain Res 151:204-17. 2003
    ..Furthermore, derivation of ENPs from the VM at the time of normal dopaminergic neurogenesis is inadequate to ensure functional dopaminergic grafts on transplantation...
  17. ncbi request reprint Increased capacity for axonal outgrowth using xenogenic tissue in vitro and in a rodent model of Parkinson's disease
    Wei Li Kuan
    Cambridge Centre for Brain Repair, Forvie Site, Robinson Way, Cambridge, UK
    Xenotransplantation 13:233-47. 2006
    ..A combination of species was used to circumvent problems relating to different gestational/developmental periods for such cells...
  18. ncbi request reprint The future of cell-based transplantation therapies for neurodegenerative disorders
    Stanley E Lazic
    Centre for Brain Repair, University of Cambridge, Cambridge CB2 2PY, UK
    J Hematother Stem Cell Res 12:635-42. 2003
    ..Finally we will discuss the prospect of using stem cells to deliver drugs and neurotrophic factors involved in neuroprotective and neuroreparative strategies in Parkinson's disease and other neurodegenerative conditions...
  19. ncbi request reprint Verbal fluency in Huntington's disease: a longitudinal analysis of phonemic and semantic clustering and switching
    Aileen K Ho
    Cambridge Centre for Brain Repair, University of Cambridge, UK
    Neuropsychologia 40:1277-84. 2002
    ..Hence, phonemic switching alone drove verbal fluency performance and this selective impairment can be explained by the progressive involvement of frontostriatal circuitry in the natural progression of HD...
  20. ncbi request reprint The heterogeneity of idiopathic Parkinson's disease
    Thomas Foltynie
    Cambridge Centre for Brain Repair, University of Cambridge, UK
    J Neurol 249:138-45. 2002
    ....
  21. doi request reprint The effects of modafinil on mood and cognition in Huntington's disease
    Andrew D Blackwell
    Department of Psychiatry, School of Clinical Medicine, University of Cambridge, Addenbrooke s Hospital, Hills Road, Cambridge, CB2 2QQ, UK
    Psychopharmacology (Berl) 199:29-36. 2008
    ..We examined whether modafinil induced similar effects in individuals with Huntington's disease (HD)...
  22. ncbi request reprint Random number generation in patients with symptomatic and presymptomatic Huntington's disease
    Aileen K Ho
    Cambridge Centre for Brain Repair, University of Cambridge, Cambridge, UK
    Cogn Behav Neurol 17:208-12. 2004
    ..The data therefore suggest that RNG is a useful, brief and reliable test of executive function and may be of value in studies investigating the longitudinal effects of disease-modifying treatment in HD...
  23. pmc Dopamine-induced proliferation of adult neural precursor cells in the mammalian subventricular zone is mediated through EGF
    Gráinne C O'Keeffe
    Department of Clinical Neurosciences, Cambridge Centre for Brain Repair, University of Cambridge, Forvie Site, Robinson Way, Cambridge CB2 0PY, United Kingdom
    Proc Natl Acad Sci U S A 106:8754-9. 2009
    ..We have therefore demonstrated a unique role for EGF as a mediator of dopamine-induced precursor cell proliferation in the SVZ, which has potential implications for future therapies in PD...
  24. doi request reprint Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease
    Angie A Kehagia
    Behavioural and Clinical Neuroscience Institute, University of Cambridge, UK
    Lancet Neurol 9:1200-13. 2010
    ..Remediation and management prospects for these cognitive deficits are based on neuropharmacological and cognitive rehabilitation approaches...
  25. ncbi request reprint A case of unilateral neglect in Huntington's disease
    Aileen K Ho
    Cambridge Centre for Brain Repair, Cambridge University, Forvie Site, Robinson Way, Cambridge, UK
    Neurocase 9:261-73. 2003
    ..However, as this was only apparent at a threshold below that normally considered acceptable (due to the resulting number of false positives), this possible account of the neglect must be viewed very cautiously...
  26. ncbi request reprint Vascular parkinsonism: a review of the precision and frequency of the diagnosis
    Thomas Foltynie
    Cambridge Centre for Brain Repair, University of Cambridge, Cambridge, UK
    Neuroepidemiology 21:1-7. 2002
    ....
  27. doi request reprint Animal models of neurodegenerative diseases
    Wendy Phillips
    Cambridge Centre for Brain Repair, ED Adrian Building, Cambridge, UK
    Methods Mol Biol 549:137-55. 2009
    ..In this chapter, we describe different models of Huntington's disease and Parkinson's disease, stereotactic surgery (used in creation of lesion models and transplantation) and finally transplantation studies in these models...
  28. doi request reprint Apolipoprotein E genotype as a risk factor for susceptibility to and dementia in Parkinson's disease
    Caroline H Williams-Gray
    Cambridge Centre for Brain Repair, Dept of Clinical Neurosciences, University of Cambridge, Forvie Site, Robinson Way, Cambridge, CB2 2PY, UK
    J Neurol 256:493-8. 2009
    ..Large scale longitudinal studies would be best placed to further evaluate any impact of APOE genotype on cognitive decline in PD...
  29. doi request reprint Switching between abstract rules reflects disease severity but not dopaminergic status in Parkinson's disease
    Angie A Kehagia
    Behavioural and Clinical Neuroscience Institute, University of Cambridge, UK
    Neuropsychologia 47:1117-27. 2009
    ..These findings suggest that switching entire task sets may be a function of extrastriatal, possibly non-dopaminergic pathology which increases as the disease progresses...
  30. ncbi request reprint Neurotrophic factors as a therapeutic target for Parkinson's disease
    Jonathan R Evans
    University of Cambridge, Cambridge Centre for Brain Repair, Department of Clinical Neuroscience, UK
    Expert Opin Ther Targets 12:437-47. 2008
    ..Furthermore, many of the key questions pertaining to such therapies, such as the optimal method of delivery, timing of treatment and selection of patients most likely to benefit, remain unanswered...
  31. doi request reprint The metabolic profile of early Huntington's disease--a combined human and transgenic mouse study
    Anna O G Goodman
    Cambridge Centre for Brain Repair, E D Adrian Building, Forvie Site, Robinson Way, Cambridge, CB2 2PY, UK
    Exp Neurol 210:691-8. 2008
    ..The reason for this is not known but may reflect a catabolic state secondary to hypothalamic pathology, as abnormalities have been reported in the hypothalamus early in the disease course...
  32. doi request reprint The relation between anger and different forms of disgust: implications for emotion recognition impairments in Huntington's disease
    Andrew J Calder
    MRC Cognition and Brain Sciences Unit, and Cambridge Centre for Brain Repair, Forvie Site, Addenbrooke s Hosptial, 15 Chaucer Road, Cambridge CB2 7EF, UK
    Neuropsychologia 48:2719-29. 2010
    ..We conclude that the related emotions of disgust and anger associated with social disapproval are frequently impaired in HD and discuss factors that might cause one emotion to show more severe impairments than the other...
  33. ncbi request reprint GABAergic immunoreactivity is predominant in neurons derived from expanded human neural precursor cells in vitro
    Meena Jain
    Cambridge University Centre for Brain Repair, Forvie Site, Robinson Way, Cambridge, CB2 2PY, UK
    Exp Neurol 182:113-23. 2003
    ..Such characterisation is important in the process of learning how to manipulate the neuronal phenotype of these cells...
  34. doi request reprint Emerging drug therapies in Huntington's disease
    Sarah L Mason
    Cambridge Centre for Brain Repair, ED Adrian Building, Forvie Site, Robinson Way, Cambridge CB20PY, UK
    Expert Opin Emerg Drugs 14:273-97. 2009
    ..This review discusses the treatments now used for HD before evaluating the newer drugs at present being explored in both the clinic and in the laboratory in mouse models of the disease...
  35. doi request reprint Huntington's disease: changes in saccades and hand-tapping over 3 years
    Chrystalina A Antoniades
    Cambridge Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Forvie Site, Cambridge, UK
    J Neurol 257:1890-8. 2010
    ..The clear-cut progression in saccadic abnormalities in the premanifest group may prove useful in the future as a predictor of time to disease onset...
  36. ncbi request reprint Dopaminergic modulation of neurogenesis in the subventricular zone of the adult brain
    Gráinne C O'Keeffe
    Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK
    Cell Cycle 8:2888-94. 2009
    ..This result has implications for the use of dopaminergic therapies in PD and in the development of such therapies focusing on upregulating SVZ neurogenesis...
  37. doi request reprint Biomarkers in Huntington's and Parkinson's Disease
    Gráinne C O'Keeffe
    Cambridge Centre for Brain Repair, Department of Clinical Neuroscience, University of Cambridge, Cambridge CB2 0PY, United Kingdom
    Ann N Y Acad Sci 1180:97-110. 2009
    ..In addition, these same markers may also help stratify each of these heterogeneous disorders into specific subtypes that share particular clinical and pathological characteristics...
  38. doi request reprint Asymptomatic sleep abnormalities are a common early feature in patients with Huntington's disease
    Anna O G Goodman
    Cambridge Centre for Brain Repair, Department of Clinical Neurosciences, Addenbrooke s Hospital, Hills Road, Cambridge, CB2 0QQ, United Kingdom
    Curr Neurol Neurosci Rep 11:211-7. 2011
    ..These results suggest that although marked changes in sleep architecture are present in early HD and can be detected using polysomnography, patients do not necessarily recognize or report these abnormalities...
  39. pmc Parkinson's disease and healthy aging: independent and interacting effects on action selection
    Laura E Hughes
    Department of Clinical Neurosciences, University of Cambridge, CB2 2QQ, United Kingdom
    Hum Brain Mapp 31:1886-99. 2010
    ..This effect is dopamine dependant, and may in part explain the clinical observation of reduced dopamine responsiveness in older patients with PD...
  40. doi request reprint How vital is sleep in Huntington's disease?
    Anna O G Goodman
    Cambridge Centre for Brain Repair, University of Cambridge, Cambridge, UK
    J Neurol 257:882-97. 2010
    ....
  41. ncbi request reprint Diagnostic potential of saccadometry in progressive supranuclear palsy
    Chrystalina A Antoniades
    University of Cambridge, Cambridge Centre for Brain Repair, Department of Clinical Neurosciences, Forvie Site, Cambridge, CB2 2PY, UK
    Biomark Med 1:487-90. 2007
    ..Conclusions: This approach appears to have considerable diagnostic potential in allowing a more accurate diagnosis of PSP, and may help particularly to eliminate misdiagnosis with other parkinsonian conditions...
  42. doi request reprint Attentional control in Parkinson's disease is dependent on COMT val 158 met genotype
    Caroline H Williams-Gray
    Cambridge Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Forvie Site, Robinson Way, Cambridge, CB2 2PY, UK
    Brain 131:397-408. 2008
    ....
  43. ncbi request reprint The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinson's disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram
    Wei Li Kuan
    Cambridge Centre for Brain Repair, Forvie Site, Robinson Way, Cambridge, CB2 2PY, UK
    Psychopharmacology (Berl) 197:279-93. 2008
    ..In a rat model of LID, we observed that animals of almost identical genetic but slightly different environmental backgrounds displayed a very different profile in terms of their development and severity of LID...
  44. ncbi request reprint Disintegration of the sleep-wake cycle and circadian timing in Huntington's disease
    A Jennifer Morton
    Department of Pharmacology, University of Cambridge, Cambridge CB2 1PD, United Kingdom
    J Neurosci 25:157-63. 2005
    ..We propose that circadian sleep disturbances are an important pathological feature of HD, that they arise from pathology within the SCN molecular oscillation, and that their treatment will bring appreciable benefits to HD patients...
  45. ncbi request reprint Is there a future for neural transplantation?
    Timothy P Harrower
    Cambridge Centre for Brain Repair, Forvie Site, Cambridge, UK
    BioDrugs 18:141-53. 2004
    ....
  46. ncbi request reprint The cellular repair of the brain in Parkinson's disease--past, present and future
    Mark Sayles
    Cambridge Centre for Brain Repair, University of Cambridge, Forvie Site, Robinson Way, Cambridge, CB2 2PY, UK
    Transpl Immunol 12:321-42. 2004
    ..Here we review the progress made in neural transplantation, both in the laboratory and in the clinic with particular attention to the development of stem cell and xenogeneic tissue based therapy...
  47. ncbi request reprint Decreased hippocampal cell proliferation in R6/1 Huntington's mice
    Stanley E Lazic
    Centre for Brain Repair, University of Cambridge, Cambridge CB2 2PY, UK
    Neuroreport 15:811-3. 2004
    ..Such a decrease in cell proliferation may be relevant to some of the deficits seen in these mice, although further work is needed to prove this...
  48. ncbi request reprint The future challenges in Parkinson's disease
    Roger A Barker
    Cambridge Centre for Brain Repair and Department of Neurology, Forvie Site, Robinson Way, Cambridge, CB2 2PY, UK
    J Neurol 251:361-5. 2004
  49. ncbi request reprint Modern therapeutic approaches in Parkinson's disease
    Simon J G Lewis
    Cambridge Centre for Brain Repair, Forvie Site, Robinson Way, Cambridge, CB2 2PY, UK
    Expert Rev Mol Med 5:1-20. 2003
    ..In this review, we discuss the emerging new therapies in PD in terms of neuroprotective agents, drugs designed to control symptoms more effectively, and finally curative cell therapies...
  50. ncbi request reprint Long-term hibernation of human fetal striatal tissue does not adversely affect its differentiation in vitro or graft survival: implications for clinical trials in Huntington's disease
    Carrie B Hurelbrink
    Cambridge Centre for Brain Repair, Forvie Site, Robinson Way, Cambridge CB2 2PY, UK
    Cell Transplant 12:687-95. 2003
    ....
  51. ncbi request reprint Cognitive impairments in early Parkinson's disease are accompanied by reductions in activity in frontostriatal neural circuitry
    Simon J G Lewis
    Cambridge Centre for Brain Repair and Department of Neurology, University of Cambridge, Cambridge, United Kingdom CB2 2EF
    J Neurosci 23:6351-6. 2003
    ..Furthermore, they suggest that fMRI may provide a valuable tool for identifying patients who may benefit from targeted therapeutic strategies...
  52. ncbi request reprint L-Dopa medication remediates cognitive inflexibility, but increases impulsivity in patients with Parkinson's disease
    Roshan Cools
    Department of Experimental Psychology, University of Cambridge, Downing Street, Cambridge CB3 9DF, UK
    Neuropsychologia 41:1431-41. 2003
    ....
  53. ncbi request reprint Migration and differentiation of transplanted human neural precursor cells
    Meena Jain
    Cambridge University Centre for Brain Repair, Forvie Site, Robinson Way, Cambridge, UK
    Neuroreport 14:1257-62. 2003
    ....
  54. ncbi request reprint Neural cells from primary human striatal xenografts migrate extensively in the adult rat CNS
    Carrie B Hurelbrink
    Cambridge Centre for Brain Repair, Forvie Site, Robinson Way, Cambridge CB2 2PY, UK
    Eur J Neurosci 15:1255-66. 2002
    ....
  55. ncbi request reprint Repairing the brain in Parkinson's disease: where next?
    Roger A Barker
    Cambridge Centre for Brain Repair, and Department of Neurology, University of Cambridge, Forvie Site, Cambridge, United Kingdom
    Mov Disord 17:233-41. 2002
  56. ncbi request reprint Dopaminergic basis for deficits in working memory but not attentional set-shifting in Parkinson's disease
    Simon J G Lewis
    Cambridge Centre for Brain Repair, Forvie Site, Addenbrooke s Hospital, Cambridge CB2 2PY, UK
    Neuropsychologia 43:823-32. 2005
    ..These results confirm that working memory deficits in PD are both psychologically specific and related to dopamine depletion. It is anticipated that greater understanding of these mechanisms will lead to future therapeutic improvements...
  57. ncbi request reprint A genome wide linkage disequilibrium screen in Parkinson's disease
    Thomas Foltynie
    Dept of Neurology, University of Cambridge, Cambridge, CB2 2PY, UK
    J Neurol 252:597-602. 2005
    ..Subgroup analysis of the most promising marker shows some evidence that microsatellite marker D1S2886 is associated with familial forms of the disease...
  58. ncbi request reprint The use of the Actiwatch-Neurologica system to objectively assess the involuntary movements and sleep-wake activity in patients with mild-moderate Huntington's disease
    Carrie B Hurelbrink
    Centre for Brain Repair, Forvie Site, Robinson Way, Cambridge CB2 2PY, UK
    J Neurol 252:642-7. 2005
    ..These results demonstrate that the Actiwatch-Neurologica activity monitor can be used to objectively assess movements in HD patients during periods of high activity as well as during sleep...
  59. ncbi request reprint Predictors of punding in Parkinson's disease: results from a questionnaire survey
    Andrew J Lawrence
    Department of Experimental Psychology, University of Cambridge, Cambridge, United Kingdom
    Mov Disord 22:2339-45. 2007
    ..These findings are similar to those seen in dopamine dysregulation syndrome, and provide further evidence for the role of impulsivity and age at disease onset in DRT-related nonmotor behavioral problems in PD...
  60. ncbi request reprint Established and emerging therapies for Huntington's disease
    Ben L C Wright
    Cambridge Centre for Brain Repair, E D Adrian Building, Forvie Site, Cambridge, UK
    Curr Mol Med 7:579-87. 2007
    ..It is likely that any successful therapy in clinical practice will involve a number of different approaches aimed at different targets in order to achieve both cell protection and cell replacement...
  61. ncbi request reprint Catechol O-methyltransferase Val158Met genotype influences frontoparietal activity during planning in patients with Parkinson's disease
    Caroline H Williams-Gray
    Cambridge Centre for Brain Repair and Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom
    J Neurosci 27:4832-8. 2007
    ....
  62. ncbi request reprint The importance of A9 dopaminergic neurons in mediating the functional benefits of fetal ventral mesencephalon transplants and levodopa-induced dyskinesias
    Wei Li Kuan
    Cambridge Centre for Brain Repair, Forvie Site, Robinson Way, Cambridge CB2 2PY, UK
    Neurobiol Dis 25:594-608. 2007
    ..These results suggest that an A9 dopaminergic neuron-enriched transplant may be the key to an effective PD cell replacement therapy through normalisation of the altered striatal expression of Cdk5/DARPP-32...
  63. ncbi request reprint Limbic neurogenesis/plasticity in the R6/2 mouse model of Huntington's disease
    Wendy Phillips
    Cambridge Centre for Brain Repair, Addenbrooke s Hospital, Cambridge, UK
    Neuroreport 17:1623-7. 2006
    ..These results support the possibility that impaired neurogenesis and/or plasticity could contribute to cognitive and psychiatric impairments in Huntington's disease...
  64. ncbi request reprint The role of learned irrelevance in attentional set-shifting impairments in Parkinson's disease
    Aleksandra Slabosz
    MRC Cognition and Brain Sciences Unit, Cambridge, England
    Neuropsychology 20:578-88. 2006
    ....
  65. ncbi request reprint L-DOPA disrupts activity in the nucleus accumbens during reversal learning in Parkinson's disease
    Roshan Cools
    Department of Experimental Psychology, Behavioural and Clinical Neurosciences Institute, University of Cambridge, Cambridge, UK
    Neuropsychopharmacology 32:180-9. 2007
    ..These data concur with evidence from studies with experimental animals and indicate an important role for the human nucleus accumbens in the dopaminergic modulation of reversal learning...
  66. ncbi request reprint Cognitive deficits and psychosis in Parkinson's disease: a review of pathophysiology and therapeutic options
    Caroline H Williams-Gray
    Cambridge Centre for Brain Repair, University of Cambridge, Cambridge, UK
    CNS Drugs 20:477-505. 2006
    ..Modafinil improves alertness in Parkinson's disease and warrants further investigation to establish its effects on cognitive performance...
  67. ncbi request reprint Abnormalities of neurogenesis in the R6/2 mouse model of Huntington's disease are attributable to the in vivo microenvironment
    Wendy Phillips
    Cambridge Centre for Brain Repair, Cambridge CB2 2PY, United Kingdom
    J Neurosci 25:11564-76. 2005
    ..These results suggest that abnormal neurogenesis in the R6/2 mouse is not attributable to an intrinsic impairment of the NPC itself but is attributable to the environment in which the cell is located...
  68. ncbi request reprint The neurological assessment of patients in vegetative and minimally conscious states
    Roger A Barker
    Department of Neurology and Cambridge Centre for Brain Repair, Addenbrooke s NHS Trust, Cambridge
    Neuropsychol Rehabil 15:214-23. 2005
    ..This multidisciplinary approach is vital in the assessment of such patients and ideally should also include neurophysiological and functional imaging paradigms...
  69. ncbi request reprint Skin and platelet alpha-synuclein as peripheral biomarkers of Parkinson's disease
    Andrew W Michell
    Cambridge Centre for Brain Repair, Forvie Site, Robinson Way, Cambridge CB22PY, UK
    Neurosci Lett 381:294-8. 2005
    ..We conclude that skin or platelet alpha-synuclein would not be an appropriate diagnostic biomarker for PD...
  70. ncbi request reprint The BDNF Val66Met polymorphism has a gender specific influence on planning ability in Parkinson's disease
    Thomas Foltynie
    Cambridge Centre for Brain Repair, University of Cambridge, Forvie Site, Robinson Way, Cambridge CB2 2PY, UK
    J Neurol 252:833-8. 2005
    ..We speculate that BDNF may interact with dopaminergic transmission and dopamine receptor stimulation in the frontostriatal circuitry, with subsequent consequences on cognition in Parkinson's disease...
  71. ncbi request reprint Dopaminergic modulation of high-level cognition in Parkinson's disease: the role of the prefrontal cortex revealed by PET
    Roshan Cools
    Department of Experimental Psychology, University of Cambridge, Cambridge, UK
    Brain 125:584-94. 2002
    ..These data suggest that L-dopa ameliorates high-level cognitive deficits in Parkinson's disease by inducing relative blood flow changes in the right dorsolateral prefrontal cortex...